0336山師さん@トレード中2020/05/29(金) 08:10:01.62ID:ArwgB/G+d IRいつかな 0337山師さん@トレード中2020/05/29(金) 08:11:32.62ID:TbiyPFRfd ギター 0338山師さん@トレード中2020/05/29(金) 08:34:32.40ID:XnWNUZZE0 好材料が出たら下がるのがそーせい 他ならストップ高三連するような奴なら10%上がるくらいで止まる 今回は下がる奴なんだろうね、だれがそんな酷いことしてるんだろう 0339山師さん@トレード中2020/05/29(金) 08:39:16.38ID:ArwgB/G+d 場中かな 0340山師さん@トレード中2020/05/29(金) 08:49:52.73ID:KhcDBwn4d 寄買い場中IRで売り 0341山師さん@トレード中2020/05/29(金) 08:53:30.60ID:n/CetrVJ0 ここは醜い顔した貧乏神が取り憑いてるからな 0342山師さん@トレード中2020/05/29(金) 08:59:42.31ID:8j7Ug6UnM>>338 普通に国内外のファンドとか機関だよ 個人が多いから簡単に狙い撃ち出来るからね すぐに狼狽とかが発生するから一斉に巻き上げられるんだとさ 0343山師さん@トレード中2020/05/29(金) 09:01:16.86ID:r5z70mz1M 誰から聞いたのかな? 0344山師さん@トレード中2020/05/29(金) 09:03:27.33ID:ArwgB/G+d 脳内だよ 0345山師さん@トレード中2020/05/29(金) 09:12:14.72ID:KhcDBwn4d IR10時パターンかな 0346山師さん@トレード中2020/05/29(金) 09:12:51.41ID:oYkZVLpV0 テラ激しいな 0347山師さん@トレード中2020/05/29(金) 09:16:50.09ID:ztSUNb230 これは絶好の仕込み時。落ちてる金を拾うようなもの 0348山師さん@トレード中2020/05/29(金) 09:23:30.30ID:CscptZh10 もう10時IRまで織り込んだよ笑 0349山師さん@トレード中2020/05/29(金) 09:33:42.68ID:CscptZh10 もし10時IRなかったら…笑 0350山師さん@トレード中2020/05/29(金) 10:05:20.50ID:irTmTR1O0 こりゃ1800はわるな 0351山師さん@トレード中2020/05/29(金) 10:08:59.33ID:xdReUShFM IRの人、コロナで隔離されてんじゃね? それか、適時開示って漢字が読めないとか 0352山師さん@トレード中2020/05/29(金) 10:11:13.11ID:YZvfcOsP0 今日のそーせいは違うぞ!! 2323まであと少し!! 0353山師さん@トレード中2020/05/29(金) 10:54:32.55ID:D7xqx9840 ※コロナ前比率マイナスです。 0354山師さん@トレード中2020/05/29(金) 11:30:45.85ID:+7fKBXlb0 ちょい待って下さいよぉ… 0355山師さん@トレード中2020/05/29(金) 11:33:09.45ID:5IqOjQqX0 あくしろよw 0356山師さん@トレード中2020/05/29(金) 13:19:31.50ID:YZvfcOsP0NIKU あああああああああああ やっぱり上で耐えられないのがここなんだよね。 結局落ちてくる・・・・ もういやっ! 0357山師さん@トレード中2020/05/29(金) 13:20:28.27ID:rwJLNrGVaNIKU 空売り外資様を舐めんなよ 0358山師さん@トレード中2020/05/29(金) 14:01:27.79ID:ArwgB/G+dNIKU 2323のひとずっと含み損耐えてるんだろうな かわいそうに 0359山師さん@トレード中2020/05/29(金) 14:16:15.28ID:D7xqx9840NIKU それよりも孤独死待ったなしの境遇の中そーせいで全財産失った奴が複数人居そうな雰囲気なんですが 0360山師さん@トレード中2020/05/29(金) 14:52:25.16ID:YZvfcOsP0NIKU>>358 同情するなら金をくれ! 0361山師さん@トレード中2020/05/29(金) 15:02:46.45ID:kpWhJiVR0NIKU 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 ・・・ ※SOSEIの成長相場の動向:今回の下押しでの調整相場(2/17:新年最高値2217、3/13最安値1051)は順調に推移しました。笑。 2020/_2/14 (終値2012) 売残高__3000 買残高_6410500 ・(2/14安値1972) ※2/13:決算 2020/_2/21 (終値2030) 売残高_26400 買残高_6176400 ・(2/21安値2004) ※2/17:決算説明会※(2/17:新年最高値2217) 2020/_2/28 (終値1645) 売残高_12800 買残高_5606500 ・(2/28:安値1590) 2020/_3/_6 (終値1538) 売残高__3800 買残高_5568200 ・(3/_6安値1526) ※3/3:MTL-CEBPA TIMEPOINT Study Initiation. 0362山師さん@トレード中2020/05/29(金) 15:03:06.68ID:kpWhJiVR0NIKU 2020/_3/13 (終値1165) 売残高_12000 買残高_4196500 ・(3/13最安値1051) 2020/_3/19 (終値1062) 売残高__2100 買残高_3760700 ・(3/19安値1058) 2020/_3/27 (終値1288) 売残高_12600 買残高_3487900 ・(3/23安値1063) ※3/25:株主総会 2020/_4/_3 (終値1225) 売残高_11600 買残高_3401500 ・(4/_3安値1211) 2020/_4/10 (終値1327) 売残高_14000 買残高_3361900 ・(4/_6安値1212) ※4/6:Discngine 3decision Selected. ※5日・25日線再GC(4/9) 2020/_4/17 (終値1419) 売残高_13200 買残高_3519700 ・(4/13安値1325) 0363山師さん@トレード中2020/05/29(金) 15:03:34.63ID:kpWhJiVR0NIKU 2020/_4/24 (終値1417) 売残高_13600 買残高_3325000 ・(4/22安値1345) 2020/_5/_1 (終値1577) 売残高_20300 買残高_3389600 ・(4/28安値1436) ※4/30: QVM149欧州承認勧告 2020/_5/15 (終値1687) 売残高_17500 買残高_3234400 ・(5/8; 5/11安値1500) ※5/7:Orexia&Inexia進捗 ※一目均衡表3役好転(5/15) 2020/_5/22 (終値1794) 売残高_14300 買残高_3362800 ・(5/18安値1722) ※5日・75日線再GC(5/18) ※9週・13週線再GC(5/19) 2020/_5/29 (終値1818) 25日線1629.84 (+11.54%) ・(5/28安値1726) ※25日・75日線再GC(5/26) ※5/28: QVM149日本承認勧告 0364山師さん@トレード中2020/05/29(金) 15:03:56.95ID:kpWhJiVR0NIKU 更なる成長の黎明期、今回はコロナショックにて、信用需給が大きく改善し、振るいは順調に推移しましたね。笑。 新型コロナの感染拡大も収束中。笑。成長戦略は着実に進捗。笑。次なる成長ステージが楽しみですね。笑。 0365山師さん@トレード中2020/05/29(金) 15:30:09.23ID:kpWhJiVR0NIKU ※日本経済新聞 電子版:「そーせいグループ、コスト管理強化」(5/28 20:35) 【コスト管理強化】 新薬の臨床試験の進行に伴い、提携先の製薬大手から得られるマイルストン収入が伸びる見通し。 販売実績に応じたロイヤルティー収入も堅調に推移する。 コスト管理を厳格化しながら研究開発に資金を充当するほか、ITシステムの刷新など効率性の向上に努める。 最終黒字の公算。 0366山師さん@トレード中2020/05/29(金) 16:02:53.88ID:8j7Ug6UnMNIKU>>359 ううっ涙 まじかるゆうこりん、、(泣) 0367山師さん@トレード中2020/05/29(金) 16:58:03.88ID:stFj5ptWaNIKU ちょい待って下さいよぉ… 0368山師さん@トレード中2020/05/29(金) 17:48:31.20ID:bqg8JUE60NIKU もう待てねー!! 0369山師さん@トレード中2020/05/29(金) 17:48:48.27ID:bqg8JUE60NIKU ウルティブログループファミリー微増 0370山師さん@トレード中2020/05/29(金) 17:49:00.53ID:bqg8JUE60NIKU 月末学会発表ラッシュ 0371山師さん@トレード中2020/05/29(金) 17:49:13.31ID:bqg8JUE60NIKU MiNAコロナ期待 0372山師さん@トレード中2020/05/29(金) 18:44:54.77ID:qoRF54yh0NIKU ゆうこりんって誰? 0373山師さん@トレード中2020/05/29(金) 18:49:23.48ID:bqg8JUE60NIKU>>372 知らないほうがいい闇 0374山師さん@トレード中2020/05/29(金) 19:01:45.33ID:kpWhJiVR0NIKU MiNA Therapeutics update: ・・・ ※MiNA Therapeutics: "Announces Research Collaboration with AstraZeneca in Metabolic Diseases". Completion of these studies, AstraZeneca will have the option to negotiate a license agreement to further develop saRNA molecules. (1/7) ※MiNA Therapeutics: "Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Combination with anti-PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumours". TIMEPOINT Study. (3/3) ※Advanced Therapies 2020: "Small activating RNAs as a novel approach for immunotherapy": David Blakey, MiNA Therapeutics. (4/1 Presented) ※Clinical Cencer Research: "MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial". Results.(5/1 Published) ※World Journal Gastroenterology: "Radiofrequency Combined with Immunomodulation for Hepatocellular Carcinoma: State of the art and innovations." RFA, checkpoint blockade and MTL-CEBPA. (5/7 Published) ※City of Hope: "Two Groundbreaking Drugs will Combat COVID-19 and its Deadliest Symptoms": MTL-CEBPA, Rossi and Habib Plan to Extend the Liver Cancer Trial to COVID Patients. (5/7) ※ASGCT: "Therapeutic saRNAstargeting CEBPA in Myeloid Cells. A Potential Immunomodulatoryswitch for Anticancer Therapy": MTL-CEBPA can potentially act as an immuno-modulatory switch. (5/12 Presented) 0375山師さん@トレード中2020/05/29(金) 19:02:10.93ID:kpWhJiVR0NIKU ↓ ※MiNA Therapeutics: "MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs". (5/27) Announced today the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research. It is the first publication in which a small activating RNA treatment (MTL-CEBPA) demonstrated clinical benefit. Publication and OUTREACH Study Update: The publication in Clinical Cancer Research summarizes the results from MiNA’s Phase I, open-label, dose escalation and dose expansion trial of MTL-CEBPA, OUTREACH, in adults with advanced Hepatocellular Carcinoma (HCC). Overall, MTL-CEBPA was well-tolerated and demonstrated pharmacodynamic target engagement, meeting the primary endpoint of the study. Furthermore, a reduction of suppressive immune cells in the tumour microenvironment as well as initial signs of potential synergistic efficacy when combined with standard of care tyrosine kinase inhibitors in HCC could be observed. These encouraging Phase I data validate the targeting of C/EBP-α as a novel therapeutic strategy in cancer and prompted a Phase Ib study further evaluating MTL-CEBPA in combination with sorafenib in HCC. Enrolment for the Phase Ib part of the OUTREACH trial was completed in Q1 2020 and initial results will be presented during a poster session at the forthcoming American Society of Clinical Oncology (ASCO) on Friday, May 29, 2020. The framework for a subsequent Phase II clinical trial is currently being designed with the objective of initiating this next stage of clinical development in the second half of 2020. 0376山師さん@トレード中2020/05/29(金) 19:02:50.44ID:kpWhJiVR0NIKU ↓ MiNA Therapeutics Press Release (5/29)
"MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting". --Observed clinical activity, including durable and complete tumour responses, suggests that MTL‑CEBPA may increase the effectiveness of sorafenib standard of care-- --Results confirm safety and tolerability of MTL-CEBPA and sorafenib combination and support continued development in liver cancer-- May 29, 2020. LONDON--MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today top line results from the Phase Ib dose escalation and cohort expansion study, OUTREACH, of lead candidate MTL-CEBPA in combination with sorafenib standard of care in patients with advanced hepatocellular carcinoma (HCC or liver cancer). The study met its primary endpoints of safety and tolerability for MTL‑CEBPA administered either concomitantly or sequentially with sorafenib. In addition, five patients experienced objective tumour responses, including two complete responses during the combination treatment. The data will be presented during a poster session at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from May 29 - May 31, 2020. 0377山師さん@トレード中2020/05/29(金) 19:03:10.28ID:kpWhJiVR0NIKU “We are delighted to have confirmed objective tumour responses in a Phase Ib study in advanced liver cancer patients who are poorly served by existing treatments,” commented Robert Habib, CEO of MiNA Therapeutics. “Combined with previous positive results, these data suggest that by reducing immune suppression in the tumour microenvironment, MTL‑CEBPA may increase the effectiveness of sorafenib standard of care.” At the data cut-off of February 1, 2020, 36 patients with advanced HCC had been treated with MTL‑CEBPA in combination with sorafenib in the Phase Ib study. 22 patients received MTL‑CEBPA and sorafenib concomitantly, and 14 patients received the two agents sequentially. Both concomitant and sequential treatment regimens were generally very well tolerated, and no maximum tolerated dose was determined. The profile of adverse events was consistent with the known safety profile of each agent and the underlying disease. In addition, concomitant sorafenib treatment did not alter the pharmacokinetics of MTL‑CEBPA. Five patients who were naïve to prior tyrosine kinase inhibitor (TKI) treatment experienced objective tumour responses, including two patients who experienced complete remission. Tumour responses were most pronounced in those TKI naïve patients with viral aetiology, where four out of nine evaluable patients experienced objective responses. 0378山師さん@トレード中2020/05/29(金) 19:04:19.74ID:kpWhJiVR0NIKU Treatment was associated with a reduction in both the number of immature immune suppressor cells as well as genetic markers of immune suppression in patient samples. These biomarker data validate the mechanism of action of MTL‑CEBPA in reducing immune suppression, which has been identified as a resistance mechanism of solid tumours to cancer treatment, including sorafenib. These encouraging Phase Ib data add to the previously published positive Phase I results in which four out of five patients experienced a durable, objective response to off-study sorafenib treatment after discontinuation of MTL‑CEBPA. As a single agent treatment, sorafenib is associated with a very low objective response rate. In a recent Phase III study, complete responses were observed in 1% of patients and partial responses were observed in 6% of patients based on RECIST 1.1 criteria in 372 patients1. The poster will be made available on the “Publications” page of MiNA’s website. ASCO Presentation information: Title: Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) Abstract no: 4601 Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Date / time: Friday, May 29, 2020 / 8:00 am Eastern Time 0379山師さん@トレード中2020/05/29(金) 19:06:35.39ID:kpWhJiVR0NIKU ↓ ※MiNA Therapeutics Publications: (ASCO Presentation Poster: 5/29up) https://minatx.com/wp-content/uploads/2020/05/ASCO-Poster-OUTREACH-Study-14MAY2020-FINAL.pdf
※ASCO 2020 Virtual Scientific Program Meeting (5/29 Today 8:00) Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary: Poster Session: [Abstract #:4601] "Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)." Conclusions: MTL-CEBPA + sorafenib is well tolerated with an acceptable safety profile. This study has confirmed signals of objective response to the combination treatment in TKI naive HCC patients with viral aetiology, warranting expanded development in these patients. Updated efficacy and safety data will be presented. Clinical trial information: NCT02716012. https://meetinglibrary.asco.org/record/186586/abstract0380山師さん@トレード中2020/05/29(金) 19:08:51.68ID:kpWhJiVR0NIKU MiNA Therapeutics Next Presentations: ・・・ ※TIDES 2020: "Small Activating RNA to CEBPa in Patients with Hepatocellular Carcinoma": Nagy Habib, MiNA Therapeutics. (9/18 12:00 Presenting) ※Keystone Symposium: Myeloid Cells and Innate Immunity in Solid Tumors: "MTL-CEBPA - Next Generation Immunotherapy Targeting Myeloid Cell Differentiation": Nagy Habib. (9/24 17:00 Presenting) ・・・ 0381山師さん@トレード中2020/05/29(金) 19:27:58.13ID:stFj5ptWaNIKU ちょい待って下さいよぉ… 0382山師さん@トレード中2020/05/29(金) 19:40:52.20ID:51nw8yvnMNIKU ちょい待って下さいよぉ… 0383山師さん@トレード中2020/05/29(金) 19:47:32.66ID:e1A0reJq0NIKU さっきから貼られてるのは悪材料? 0384山師さん@トレード中2020/05/29(金) 19:49:04.59ID:3Moj4jWZaNIKU>>383 空売り外資様を舐めんなよ 0385山師さん@トレード中2020/05/29(金) 19:58:15.72ID:bqg8JUE60NIKU>>383 逆だボケって言ってほしいんだろ? 0386山師さん@トレード中2020/05/29(金) 21:22:56.67ID:smL25+ps0NIKU おいおいすごいことになってきたな ホルダーおめ 0387山師さん@トレード中2020/05/29(金) 21:38:02.28ID:zay884n+0NIKU そーヘプHPパイプラインにアッヴィ表記おめ 0388山師さん@トレード中2020/05/29(金) 21:50:06.40ID:D7xqx9840NIKU 安心はできん ただの事務的な手続きと言ってしまえばそれまでだ 0389山師さん@トレード中2020/05/29(金) 21:50:44.87ID:e1A0reJq0NIKU ロゴ画像書き換えただけで大喜びのホルダー 0390山師さん@トレード中2020/05/29(金) 21:55:08.20ID:D7xqx9840NIKU ヤフ板とかTwitterのチェックは欠かさず情報に敏感で即レスの売り煽り風ネガティブホルダー 0391山師さん@トレード中2020/05/30(土) 01:04:06.35ID:VlCAnumn0 HP色々変わった。 コロナでやることなかったかな。 0392山師さん@トレード中2020/05/30(土) 03:29:49.35ID:5WswRQIa0 ちょい待って下さいよぉ… 0393山師さん@トレード中2020/05/30(土) 04:43:07.26ID:DZImwBrb0>>391 そーせいの人がhp作ってんの? 昔のファナックかよwww 0394山師さん@トレード中2020/05/30(土) 06:05:26.63ID:P8UMW86f0 AZD4635 Presentations update: ・・・ ※AstraZeneca Press Releases: "AstraZeneca Advances the Science of Cancer Medicine with Practice-Changing Data at the ASCO20 Virtual Scientific Program". (5/13) ※ASCO 2020 Virtual Scientific Program Meeting: [Abstract 5518]: (5/29 Presented: Video, Poster 5/29 up ) "A Phase I, Open-label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of AZD4635 both as Monotherapy and in Combination in Patients with Advanced Solid Malignancies: Results from Prostate Cancer Patients (NCT02740985)." ・Abstract: https://meetinglibrary.asco.org/record/187566/abstract ・Video: https://meetinglibrary.asco.org/record/187566/video ・Poster: https://meetinglibrary.asco.org/record/187566/poster0395山師さん@トレード中2020/05/30(土) 06:06:15.33ID:P8UMW86f0 ↓ Conference Coverage: (5/29) ・UroToday - ASCO 2020 therapeutic development strategies for prostate cancer, bipolar androgen therapy for prostate cancer treatment, prostate cancer AZD4635 monotherapy, capivasertib plus docetaxel and prednisolone chemotherapy.
※UroToday: ASCO 2020 Prostate Cancer: ”ASCO 2020: Promising Therapeutic Targets in Prostate Cancer”. (5/29) In this presentation, Dr. Aparicio discussed Abstracts 5517, 5518, and 5520, representing three promising treatment strategies under development in prostate cancer. [Abstract 5517]: ・・・ [Abstract 5518]: "A Phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients". Extracellular adenosine accumulates in hypoxic tumor environments and is associated with decreased immune response. This immune suppression is thought to be in part due to adenosine binding to the T-cell adenosine 2A receptor (A2aR). There is interest in targeting the A2aR based on data showing A2aR upregulation in response to treatment with the anti-PD-L1 antibody durvalumab, and data showing enhanced T-cell activation with combination PD1/PDL1 and A2aR axis therapy. 0396山師さん@トレード中2020/05/30(土) 06:06:37.30ID:P8UMW86f0 This abstract presented data as part of a larger multi-center Phase I trial in multiple cancers looking at AZD4635 monotherapy or in combination with specific agents across multiple cancer types. The trial utilizes a Bayesian logistic regression model-based approach in its design. In prostate cancer patients, AZD4635 was administered as monotherapy or in combination with durvalumab. The results from a cohort of heavily pretreated prostate cancer patients (median five prior treatments) showed response in a subset of patients and suggest that progression-free survival was prolonged in patients with evidence of higher adenosine-associated gene expression relative to those lacking this signature. [Abstract 5520]: ・・・ Together these trials suggest a framework for ongoing prostate cancer therapeutic development. Improved disease classification from biologic insights can lead to “reverse translation”, where biologically informed therapies are tested within disease subclasses using novel trial designs to overall accelerate the development of treatments that improve patient outcomes. ・Presented by: Ana Aparicio, MD, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. ・Written by: Alok Tewari, MD, PhD, Medical Oncology Fellow at the Dana-Farber Cancer Institute, Boston, Massachusetts, at the 2020 American Society of Clinical Oncology Virtual Annual Meeting, May 29th-May 31st, 2020. 0397山師さん@トレード中2020/05/30(土) 06:07:00.34ID:P8UMW86f0 AZD4635 Next Presentations: ・・・ ※AACR: "Clinical Pharmacology of AZD4635: Integration of PK data from Cancer Patients and Healthy Volunteer Clinical Trials to Provide Dosing Recommendations". (6/22 9:00: Virtual) ・https://www.abstractsonline.com/pp8/#!/9045/presentation/11313 ※AACR: "Targeting A2aR (AZD4635) in Mouse Pten-Deficient Prostate Cancer". (6/23 9:05-9:15: Virtual) ・https://www.abstractsonline.com/pp8/#!/9045/presentation/6910 ※AstraZeneca Q2 2020 Results: (7/30) ・・・ 0398山師さん@トレード中2020/05/30(土) 09:46:49.72ID:tEXAH6Wq0>>373 興味本位で調べるんじゃなかった・・・ 0399山師さん@トレード中2020/05/30(土) 11:43:27.52ID:4P5uWGCf0 なんでこんなにも静かなの? アッヴィの名前があるんやで 0400山師さん@トレード中2020/05/30(土) 12:15:18.60ID:5WswRQIa0 ちょい待って下さいよぉ… 0401山師さん@トレード中2020/05/30(土) 12:38:00.05ID:ChGirCqbd>>399 だまってろ 0402山師さん@トレード中2020/05/30(土) 12:59:38.88ID:bG1VtdmLM>>399 再開と決まらなきゃ意味ない、第一三共も無くなってるし 0403山師さん@トレード中2020/05/30(土) 12:59:43.80ID:bG1VtdmLM オワタ 0404山師さん@トレード中2020/05/30(土) 13:03:32.60ID:ewSRdaRV0 ※科学や英語に堪能な人が持ってきた情報に文句を言うだけの簡単なお仕事です。 0405山師さん@トレード中2020/05/30(土) 13:08:05.06ID:bG1VtdmLM MiNAは発表内容リリース 0406山師さん@トレード中2020/05/30(土) 13:12:21.74ID:4P5uWGCf0 でもわざわざアッヴィの名前書くか? 0407山師さん@トレード中2020/05/30(土) 13:26:17.10ID:VlCAnumn0 第一三共が消えて、mシリーズが残っている意味を考えよう 0408山師さん@トレード中2020/05/30(土) 13:33:43.39ID:Q2W00ICc0 M1来たら実際15000は行くでしょ 0409山師さん@トレード中2020/05/30(土) 14:03:19.31ID:RHJzdHPPa アラガンが会社としてなくなったわけでもないのにわざわざアッヴィと記載変更するのかという謎はあるね 0410山師さん@トレード中2020/05/30(土) 14:12:42.36ID:a4fypEVs0>>399,406 アッヴィ名の表記はあくまで便宜上のもので特に深い意味はないのかもしれない アッヴィとの合併によってアラガンが無くなった今いつまでもアラガン名で載せておくわけにはいかず、かと言って進退が定まっていない状態ではパイプラインから勝手に外す事もできないだろうから 0411山師さん@トレード中2020/05/30(土) 14:12:48.86ID:sPtQoYut0 第一三共に切られてるじゃん